COR

Cencora, Inc.

Fundamental data last updated:November 5, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Medical - Distribution

Exchange

NYSE

County of HQ

US

Next Earnings Date

Pending Announcement

Business Summary

Cencora, Inc. functions as a global leader in the sourcing and distribution of pharmaceutical products, with operations spanning both the United States and international markets. Within its U.S. Healthcare Solutions segment, the company supplies a broad spectrum of pharmaceutical items, including generic and injectable medications, over-the-counter health products, and home healthcare equipment. Its extensive client network includes acute care hospitals, health systems, a variety of retail and mail-order pharmacies (independent, chain, long-term care), medical clinics, and other healthcare providers. This division also manages the distribution of crucial specialized pharmaceutical products like plasma, blood derivatives, and vaccines. Beyond product supply, Cencora offers comprehensive support services, such as pharmacy management, staffing solutions, and strategic consulting. It develops and implements supply management software, provides packaging services for both institutional and retail healthcare settings, and assists with clinical trial support, post-market approval processes, and commercialization strategies. For biotechnology and pharmaceutical manufacturers, the company delivers data analytics, outcomes research, and other specialized services. Furthermore, Cencora serves the animal health market, providing pharmaceuticals, vaccines, parasiticides, diagnostics, and micro feed ingredients for both companion and production animals. It also offers sales force support to manufacturers and specialized services to medical professionals, particularly oncologists, as well as to hospitals and dialysis clinics. The International Healthcare Solutions division concentrates on global pharmaceutical wholesale activities, associated services, and worldwide commercialization support. It ensures the efficient distribution of medicines, various healthcare goods, and related services to an international customer base comprising pharmacies, doctors, health centers, and hospitals. This segment also delivers specialized transportation and logistics solutions specifically designed for the biopharmaceutical sector. Founded in 1871, the company was formerly known as AmerisourceBergen Corporation before adopting the name Cencora, Inc. in August 2023. Its corporate headquarters are situated in Conshohocken, Pennsylvania.

 


VALUATION

P/E

24.99

Market Cap ($M USD)

$64.47B

Forward P/E

17.12

PEG

2.43

PRICE TO SALES

0.19

PRICE TO BOOK

21.39

EV / EBITDA

14.25

5-Year Average P/E

Free Cash Flow Yield

6.30%

DCF Value

$570.93

Graham Number

$69.50

Price to FCF

15.88

EV to FCF

18.07

Earnings Yield

4.02%

FCF Yield

6.30%

DIVIDEND

Yield

0.71%

Annual Payout

$2.40

Payout Ratio

17.83%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

$13.59

Next Year EPS Growth Estimate

$19.73

Next Year Revenue Growth Estimate

$352.05B

Return on Equity (ROE)

106.43%

FREE CASH FLOW

Operating Margin

1.30%

Debt-to-Equity

3.84

Piotroski F-Score

7

Altman Z-Score

4.71

Return on Invested Capital (ROIC)

12.75%

Current Ratio

0.93

Quick Ratio

0.58

Net Debt to EBITDA

1.73

Interest Coverage

8.71

Gross Profit margin

3.71%

FCF PER SHARE

$21.02

REVENUE PER SHARE

$1722.89

Gainseekers Quantitative Analysis

Summary

Cencora, Inc. presents a compelling yet complex valuation narrative. Recent pricing indicated it traded significantly below its DCF value, suggesting a potential undervaluation. However, a Price/Book ratio of over 20 raises eyebrows, hinting at a premium market perception. The Forward P/E of 16.71 is more palatable, aligning with a solid growth outlook. With an Altman Z-score of 4.7, the company appears financially robust, minimizing bankruptcy risk and supporting its growth trajectory.

AI Exposure / Tech Reliance

Operating in the Medical Distribution sector, Cencora is strategically positioned to leverage AI and tech advancements. The healthcare industry is increasingly integrating AI for supply chain optimization and predictive analytics. This positions Cencora to enhance operational efficiency and maintain a competitive edge.

The Bull Case

For the discerning value investor, Cencora offers a tantalizing proposition. With an ROIC of 12.75%, the company demonstrates impressive capital efficiency, translating into robust shareholder returns. A Piotroski F-Score of 7 signals strong financial health, while a Free Cash Flow Yield of 6.45% underscores its ability to generate cash. These metrics suggest a company with pricing power and operational resilience, making it an attractive buy.

The Bear Case

Despite its strengths, Cencora is not without its pitfalls. The Price/Sales ratio of 0.19 and a Price/Book ratio exceeding 20 suggest a potentially overvalued stock. The operating margin of just 1.3% raises concerns about profitability in a competitive market. Additionally, a Debt/Equity ratio of 3.84 indicates significant leverage, which could pose risks if market conditions deteriorate.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$357.75

Institutional Ownership %

1-Year Beta

0.58

Insider Buying % (6 Mo)

Distance to 52-Week High

11.75%

Distance to 52-Week Low

27.53%

EARNINGS SURPRISE %

2.99%

50-DAY SMA

$323.38

200-DAY SMA

$317.09

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.